Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTA-BPP PET/CT in Triple-Negative Breast Cancer
NCT06203119Phase 1Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-DOTA-BPP in triple-negative breast cancer (TNBC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Safety and tolerability of 68Ga-DOTA-BPP at Day 1 and Biodistribution of 68Ga-DOTA-BPP in normal organs. Started Mar 2024; status: completed.
02
Drugs
68Ga-DOTA-BPP
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06203119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203119.